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Background: Castanea mollissima Blume (Chinese chestnut), as a food product is known for its various nutrients
and functional values to the human health. The present study was carried out to analyze the anti-diabetic
complications and anti-cancer activities of the bioactive compounds present in C. mollissima.
Methods: The kernels (CK), shells (CS) and involucres (CI) parts of C. Blume were extracted with 90% alcohol. The
water suspension of these dried alcohol extracts were extracted using EtOAc and n-BuOH successively. The n-BuOH
fraction of CI (CI-B) was isolated by silica gel column, Sephadex LH 20 column and preparative HPLC. The isolated
compounds were identified by 1H-NMR, 13C-NMR, HMBC, HMQC and ESI-Q-TOF MS, All the fractions and compounds
isolated were evaluated on human recombinant aldose reductase (HR-AR) assay, advanced glycation end products
(AGEs) formation assay and human COLO 320 DM colon cancer cells inhibitory assay.
Results: CI-B was found to show a significant inhibitory effect in above biological screenings. Six flavonoids and
three polyphenolic acids were obtained from CI-B. They were identified as kaempferol (1), kaempferol-3-O-[6''-O-(E)-p-
coumaroyl]-β-D-glucopyranoside (2), kaempferol-3-O-[6''-O-(E)-p-coumaroyl]-β-D-galactopyranoside (3), kaempferol-
3-O-[2''-O-(E)-p-coumaroyl]-β-D-glucopyranoside (4), kaempferol-3-O-[2", 6"-di-O-(E)-p-coumaroyl]-β-D-glucopyranoside
(5) and kaempferol-3-O-[2", 6"-di-O-(E)-p-coumaroyl]-β-D-galactopyranoside (6), casuariin (7), casuarinin (8) and castalagin
(9). Compounds 2–9 were found to show higher activity than quercetin (positive control) in the AR assay. Compounds
3–6, 8, and 9 showed stronger inhibitory effects than amino guanidine (positive control) on AGEs production.
Compounds 4–6, 7, and 8 showed much higher cytotoxic activity than 5-fluorouracil (positive control) against the
human COLO 320 DM colon cancer cells.
Conclusions: Our results suggest that flavonoids and polyphenolic acids possesses anti-diabetes complications and
anti-cancer properties, and they were presumed to be the bioactive components of Castanea mollissima Blume.
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Castanea mollissima Blume (family Fagaceae), with the
Chinese name “Ban li” (chestnut) is widely distributed in
Asian areas, such as China, Korea and Viet Nam. Chestnut
fruits are highly regarded and widely consumed through-
out Asia, Europe and America. Various commercial forms* Correspondence: sypugaohy@163.com; zhanlb@dlmedu.edu.cn
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unless otherwise stated.are available. Ban li is not only used as a food product
for its various nutrients, but also used as a traditional
Chinese medicine, including the flowers, leaves, and
twigs to have been used to treat gastroenteritis, bron-
chitis and regurgitation for hundreds years [1]. It is no
doubt that chestnuts have considerable potential value as
functional foods [2].
To increase and find much more functional values for
the Chinese chestnut, our previous work on the chem-
ical constituents and bioactivity of it resulted in the iso-
lation of many flavonoids and phenolic acids [3-6]. In
the continuous assessing its bioactivity and finding moreLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cancer activity of all fractions of alcohol extracts of ker-
nels (CK), shells (CS) and involucres (CI) were evaluated
on human recombinant aldose reductase (HR-AR) assay,
advanced glycation end products (AGEs) formation
assay and human COLO 320 DM colon cancer cells in-
hibitory assay in the present work, respectively.
Diabetes, as a complex metabolic disorder caused by
insulin insufficiency and/or insulin dysfunction, is char-
acterized by aberrant blood glucose and insulin levels
[7]. Diabetic complications, including retinopathy, neur-
opathy, nephropathy, and arteriosclerosis are considered
as risk factors for morbidity and death. Moreover, the
diabetic patients are also susceptible to many diseases,
including the cancer. For example, colorectal cancer
which is the third leading cause of cancer-related death
[8], is much easier happened in diabetic patient [9].
Many studies on chestnut seeds and other parts of this
plant emphasised on the anti-oxidant property [2,10],
while, the present work were to value their anti-diabetes
complications and against the connecting cancer activity,
also to find the part with much functional values.
Methods
Plant material
The kernel, shells and involucres parts of C. mollissima
were collected respectively in September, 2005 in Qianxi
County of Hebei province, and identified by Professor
Sun Qishi (College of Traditional Chinese Medicine,
Shenyang Pharmaceutical University). The voucher spec-
imens were deposited at the Key Laboratory of Structure-
Based Drug Design & Discovery of Ministry of Education
(No.ZB2005-026-028).
Chemical and reagents
Dibasic sodium phosphate, sodium dihydrogen phos-
phate, D,L-glyceraldehyde, human recombinant aldose
reductase (HR-AR), AG, quercetin, critric acid monohy-
drate, natrium carbonicum, sodium azide, gelatin and
sulphuric acid were purchased from Wako Pure Chem-
ical Industries, Ltd. (Osaka, Japan). Sodium bicarbonate,
sodium chloride, potassium dihydrogen phosphate and
ethanol were supplied by Nacalai Inc. (Kyoto, Japan).
Tween 20, bovine serum albumin, glucose, O-phenylene-
diamine dihydrochloride, phosphate buffered saline, fetal
bovine serum (FBS), steroyl myristoyl phosphatidylcho-
line glycine (SMPC Gly), 3-(4, 5-dimethylthazol-2-yl)-2,
5-diphenyl tetrazolium bromidetetrazolium salt (MTT)
were purchased from Sigma-Aldrich company, Ltd. (St.
Louis, MO, U.S.A.). NADPH was provided by Oriental
Yeast Co., Ltd. (Tokyo, Japan). Anti-AGE antibody and
goat anti-mouse IgG, HRP conjugate-secondary antibody
Millipore (Merck U.S.A) were purchased from Trans-
genic Inc. (Hyogo, Japan). Silica gel 60 F254 TLC plates(Merck, U.S.A), silica gel 60 N (100–200 μm) and ODS
were purchased from Kanto Chemical (Tokyo, Japan).
DMSO was purchased from Wako Pure Chemical In-
dustries, Ltd (Japan). Kaempferol-3-O-β-D-glucopyrano-
side was isolated from liquorice, and was identified by
NMR and MS data [11].
Instrument
Analysis HPLC was carried out on Waters 510 with
Waters 484 detector (waters, USA) using a kromasil C18
column (4.6 × 200 mm, Rainbow). Preparative HPLC was
carried out on JASCO PU-2087 with JASCO PU-2075
detector (JASCO, Japan) using a HiQ sil C18 column
(10 × 200 mm, YATECH). ESI-MS spectra were recorded
on a Bruker esquire 2000 mass spectrometer. NMR
spectra (1H-, 13C-NMR, HMBC and NOESY) were mea-
sured and recorded on Bruker AVANCE 600 (Bruker,
Newark, DE) in DMSO using TMS as internal standard.
Infrared (IR) spectra were measured on a Fourier trans-
form infrared spectrometer (IFS-55; Bruker).
HR-AR assay
Aldose reductase activities of samples were assayed spec-
trophotometrically by determining the decrease in
NADPH concentration at 340 nm in a UV-2201 Pharma
Spec UV–vis spectrophotometer (Shimadzu, Japan). The
reaction mixture contained 0.14 M phosphate buffer
pH 6.2, 700 μL; 0.15 mM NADPH, 100 μL; 3 × 10−2
units/mL AR, 100 μL; 10 mM D,L-glyceraldehyde,
3.3 mg/mL extracts or 1 mg/mL compounds in DMSO,
3 μL, in a total volume of 1 mL with a final concentra-
tion of 10 μg/mL for extracts and 3.3 μg/mL for com-
pounds. The reference blank contained all of the above
reagents, and buffer instead of AR, to correct for non-
specific reduction of NADPH. The control had only the
sample solvent instead of the sample to correct for re-
duction of NADPH without inhibitor of AR (ARI). The
reaction was initiated by the addition of substrate, and it
was monitored spectrophotometrically for 3 min. All
values were averages of three independent experiments
[12]. The inhibition ratio of AR was calculated by follow-
ing equation:
Inhibition %ð Þ ¼ 1 − Δ ABSsample − Δ ABSblank
 
 Δ ABScontrol – Δ ABSblankð Þ  100
Inhibit formation of AGEs assay
The AGEs reaction solution (200 μL) was composed of
16 mg/mL bovine serum albumin, 50 μL; 0.1 M sodium
phosphate buffer (pH 7.4), 96 μL; 144 mg/mL glucose,
50 μL; 0.5 mg/mL sample in DMSO, 4 μL with a final
concentration of 10 μg/mL. The sample blank, control
solvent and blank solvent contained all of the above
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glucose in the sample blank, sample solvent instead of
sample in the control solvent, and sample solvent in-
stead of sample, buffer instead of glucose in the blank
solvent. After incubating at 37°C for 7 days, the amounts
of AGE products were determined by enzyme-linked im-
munosorbent assay (ELISA) [13]. Noncompetitive ELISA
assays were performed at room temperature. Each well
was incubated for 1 h with 0.1 mL of an AGE sample to
be tested or its corresponding control sample in 50 mM
carbonate buffer (pH 9.7) and washed three times with
washing buffer (phosphate-buffered saline containing
0.05% Tween 20). Each well was then blocked for 1 h
with 0.2 mL of 2.5% gelatin in 5 mM carbonate buffer
(pH 9.7). Each well was washed three times with wash-
ing buffer and incubated for 1 h with 0.1 mL of anti-
AGE antibody (50 ng/mL). Wells were then washed
three times with washing buffer and incubated for 1 h
with 0.1 mL of goat anti-mouse IgG, HRP conjugate-
secondary antibody (Millipore, Merck) and then washed
three times, followed by reaction with o-phenylenedi-
amine dihydrochloride and hydrogen peroxide mixture.
The reaction was terminated by adding 1 M sulfuric
acid, and the absorbance at 492 nm was read on a
micro-plate reader (MPR A4i II TOSOH). All values are
averages of three independent experiments, each done in
triplicate [14]. The percentage inhibition of AGE pro-
duction was calculated by the following equation:
Inhibition %ð Þ ¼ ½1− Asample −Asample blank
 
 Acontrol solvent −Ablank solventð Þ100
Cytotoxic assay
Human COLO 320 DM colon cancer cells (passage-10)
were maintained in RPMI-1640 medium supplemented
with 10% FBS and SMPC Gly at 37°C in an incubator.
The cytotoxicity was determined by the MTT method.
Briefly, exponentially growing cells, 100 μl, were at-
tached at 5 × 104 cells/well, in 96-well plates, and the
cellular viability was determined after 24 h, 48 h, and
72 h administration of the extractions (100 μg/mL)
100 μL. Cells were incubated with MTT tetrazolium salt
for 1 h at 37°C, and the formation of formazan was mea-
sured by a microplate reader (MPR A4iIITOSOH). All
values are averages of two independent experiments,
each done in triplicate. The percentage inhibition of cell
growth was calculated by the following equation:
Inhibition %ð Þ ¼ 100 − A1=A0ð Þ  100½ 
Where A0 is the absorbance of the control at 500 nm
after incubations, and A1 is the absorbance in thepresence of the samples. The study was performed in ac-
cordance with the Declaration of Helsinki.
Extraction and isolation
Air-dried three parts of kernels 6 kg (CK), shells 5 kg (CS)
and involucres 10 kg (CI) of were C. mollissima crushed
and extracted with ethanol-water (90:10, v/v) (CK: 36 L;
CS: 30 L and CI: 60 L) for three times (for 2 h × 3) respect-
ively, then, the solutions were concentrated under reduced
pressure using a rotary evaporator less than 40°C, to give
extracts (CK 953.2 g, 15.89%; CS 257.4 g, 5.15%; CI
305.6 g, 3.06%), respectively. The extracts were suspended
in distilled water (CK: 6 L, CS: 5 L, and CI: 10 L) and par-
titioned successively with the same volume EtOAc and n-
BuOH successively. After removing organic solvents, three
EtOAC soluble fractions CK-A (30.2 g, 0.50%), CS-A
(35.9 g, 0.72%), CI-A (95.7 g, 0.96%) and three n-BuOH
soluble fractions CK-B (61.5 g, 1.03%), CS-B (21.8 g,
0.44%), CI-B (62.1 g, 0.62%), along with three aqueous
parts CK-W (811.9 g, 13.53%), CS-W (140.6 g, 2.81%), CI-
W (125.9 g, 1.26%) were obtained. Each part was vacuum-
packed and stored at −20°C until use.
Part of CI-B (60 g) was taken and mixed with 180 g sil-
ica then applied to a 85 cm× 10 cm (inside diameter) silica
gel column and eluted with different ratios of EtOAc and
MeOH (10:1, 10:2, 10:4, 10:6, 10:8, 1:1, 1:5, 0:1) to give 10
fractions based on the results of TLC experiment. Fraction
2 (9.75 g) eluted with EtOAc-MeOH (10:1) was further
separated into 12 sub-fractions by a 60 cm× 7 cm (inside
diameter) silica gel column based on the results of TLC
experiment. Sub-fraction 7 (1.25 g) eluted with Hexane-
EtOAc (1:3) was purified by preparative HPLC with
MeOH-H2O (60:40 v/v, 1.5 mL/min) on a C18-MS-II-wa-
ters column (10 × 250 mm) to yield compound 1 (30 mg).
Subfraction 9 (0.87 g) eluted with Hexane-EtOAc (3:1)
was purified by a 40 cm× 6 cm (inside diameter) ODS gel
column with MeOH-H2O (30:70, 40:60, 50:50, 60:40,
100:0 v/v) and preparative HPLC with MeOH-H2O
(55:45 v/v, 1.5 mL/min) on a C18-MS-waters column
(10 × 250 mm) to yield compound 5 (30 mg) and com-
pound 6 (15 mg). Sub-fraction 10 (1.50 g) eluted with
Hexane-EtOAc (6:1) was purified by preparative HPLC
with MeOH-H2O (55:45 v/v) on a C18-MS-waters column
(10 × 250 mm) to yield compounds 2 (7 mg), 3 (30 mg)
and 4 (25 mg). Fraction 3 (26.0 g) eluted with EtOAc-
MeOH (10:1) was further separated into 8 sub-fractions
by a 80 cm × 9 cm (inside diameter) silica gel column.
Compounds 7–9 was obtained from sub-fraction 5
(5.36 g) which was eluted with Hexane-EtOAc (6:1) by a
50 cm× 7 cm (inside diameter) ODS gel column with
MeOH-H2O (30:70, 40:60, 50:50, 60:40, 100:0 v/v) and an
80 cm× 4 cm (inside diameter) Sephadex LH-20 column
with MeOH-H2O (50:50 v/v). Structures of compounds
1–9 were shown in Figure 1.
Figure 1 The structures of compounds 1–9.
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Compound 6 (1.0 mg) was dissolved in MeOH (9 mL)
containing HCl (1 mL) and refluxed on a heated (80°C)
water bath for 3 h. After cooling, the reaction mixture
was concentrated and dried under reduced pressure,
then analyzed by TLC using the solvent system CHCl3–
MeOH–H2O (20:10:1) for identification of the complete
reaction. The dried residues dissolved in EtOAc, and
partitioned with water. The water solution was analyzed
and subjected to HPLC with optical detector using a
Kaseisorb LC NH2-60-5 column (4.6 mm i.d. × 250 nm)
with CH3CN–H2O (v:v = 85:15, Flow: 0.8 mL/min) as
the mobile phase. Identification of D-galactose was car-
ried out by comparison of the retention time (13.2 min)
and OD (+) with authentic samples.
Results
Structural determination of compound 6
Kaempferol-3-O-[2", 6"-di-O-(E)-p-coumaroyl]-β-D-galac-
topyranoside (6) was obtained as a yellow powder with a
negative optical rotation. Its structure identification was
achieved by mass and NMR spectroscopy (Additional
files 1, 2, 3, 4, 5, 6 and 7), including two dimensional cor-
related NMR (NOESY, HMQC, HMBC). Its molecular
formula was established as C39H32O15 by means of ESI-
Q-TOF MS which showed an [M +H]+ ion peak at m/z741.1824 (calcd 741.1819 for C39H33O15).
1H- and 13C
NMR spectral data of 6 (Table 1) showed the presence of
a kaempferol residue, two p-coumaroyl groups and one
sugar unit. The HMBC spectrum (Figure 2) clarified the
attachment of the sugar group at C-3 position based on a
correlation between the anomeric proton signal at δH
5.54 (d, J = 7.6) with C-3 (104.65). The attachments for
two p-coumaroyl groups at C-2″ and C-6″ were based
on correlations between δH 5.38 (dd, J = 9.6, 8.0, H-2″)
with δC 168.23 (C-9″′), and, δH 4.19, 4.36 (dd, 11.6, H-
6") with δC 168.21 (C-9""), respectively. The trans form
configurations for their double bonds at C-7''', 8''' and C-
7'''', 8'''' positions were confirmed by the coupling con-
stant values 15.6 Hz for H-7''' and H-7'''' [15]. The sugar
unit was identified as galactose after the sample was dealt
with the acid hydrolysis and compared the tR with the au-
thentic sample by HPLC analysis using a Kaseisorb LC
NH2-60-5 column (4.6 mm i.d. × 250 nm), CH3CN–H2O
as the mobile phase. Compound 6 was identified as
kaempferol-3-O-[2", 6"-di-O-(E)-p-coumaroyl]-β-D-galac-
topyranoside at finally.
Effects of fractions and compounds in HR-AR, AGEs and
Cytotoxic assay
All crude materials and soluble fractions (EtOAc, n-
BuOH and water part) of kernels (CK, CK-A, CK-B, CK-
Table 1 NMR spectra data of compound 6 in CD3OD





6 6.06 (1H, br.s) 99.79 d 5, 7, 8, 10
7 165.32 s




2′, 6′ 7.96 (2H, d, 8.8) 131.95 d 2, 4′
3′, 5′ 6.87 (2H, d, 8.8) 116.10 d 4′, 1′
4′ 161.13 s
1′′ 5.54 (1H, d, 8.0 ) 100.85 d 3, 2′′
2′′ 5.38 (1H, dd, 9.6,8.0) 73.98 d 1′′, 3′′, 9′′′
3′′ 3.82 (1H, m) 73.13 d 2′′
4′′ 3.88 (1H, m) 70.53 d 2′′
5′′ 3.85 (1H, m) 74.90 d
6′′ 4.19 (1H, dd, 11.6) 64.15 t 9′′′′
4.36 (1H, dd, 11.6)
1′′′ 127.09 s
2′′′, 6′′′ 7.46 (2H, d, 8.4) 131.00 d 4′′′, 7′′′
3′′′, 5′′′ 6.79 (2H, d, 8.4) 116.59 d 1′′′, 4′′′
4′′′ 160.94 s
7′′′ 7.69 (1H, d, 15.6) 146.68 d 6′′′, 8′′′, 9′′′
8′′′ 6.40 (1H, d, 15.6) 115.12 d 1′′′, 9′′′
9′′′ 168.23 s
1′′′′ 126.87 s
2′′′′, 6′′′′ 7.27 (2H, d, 8.4) 130.92 d 4′′′′, 7′′′′
3′′′′, 5′′′′ 6.79 (2H, d, 8.4) 116.59 d 1′′′′, 4′′′′
4′′′′ 160.87 s
7′′′′ 7.40 (1H, d, 15.6) 146.35 d 6′′′′, 8′′′′, 9′′′′
8′′′′ 6.05 (1H, d, 15.6) 114.43 d 9′′′′
9′′′′ 168.21 s
Figure 3 Inhibition ratio of all parts of the kernel (CK-A, CK-B,
CK-W, CK), shell (CS-A, CS-B, CS-W, CS) and involucre (CI-A, CI-B,
CI-W, CI) (10 μg/mL) in the AR assay, AGEs production and
COLO 320DM proliferation. Positive Control (PC): Quercetin
(3.3 μg/mL) for AR assay, AG (amino guanidine, 0.2 mM) for AGEs
production and 5-Fu (5-fluorouracil, 50 μg/mL) for COLO 320DM
proliferation, respectively.
Figure 2 Key HMBC correlations of compound 6.
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CI-A, CI-B, CI-W) were evaluated on AR, AGEs and the
growth inhibitory activity aginst human COLO 320 DM
colon cancer cells. Among these fractions, the n-BuOH
soluble fraction of involucres (CI-B) was found to be sig-
nificantly more active than others (Figure 3), and its in-
hibitory rates were 88.6 ± 2.3% in AR, 77.0 ± 5.8% in
AGEs, and 81.3 ± 3.7% in cytotoxic assay respectively.
Effective compounds from CI-B were further studied. Six
flavonoids, kaempferol (1), kaempferol-3-O-[6"-O-(E)-p-
coumaroyl]-β-D-glucopyranoside (2), kaempferol-3-O-[6"-O-(E)-p-coumaroyl]-β-D-galatopyranoside (3), kaem-
pferol-3-O-[2"-O-(E)-p-coumaroyl]-β-D-glucopyranoside
(4), kaempferol-3-O-[2", 6"-di-O-(E)-p-coumaroyl]-β-D-
glucopyranoside (5), kaempferol-3-O-[2", 6"-di-O-(E)-p-
coumaroyl]-β-D-galactopyranoside (6), and three polyphe-
nolic acids, casuariin (7), casuarinin (8), and castalagin (9)
were obtained. Structures of compounds (see Figure 1)
were elucidated by the spectroscopic methods, including
UV, ESI-MS, NMR experiments, and comparing their
spectral data with reported in the references [3,16,17]. The
inhibitory activities of compounds 1–9 were shown in
Table 2.
Physicochemical data of compounds 2–9
kaempferol-3-O-[6"-O-(E)-p-coumaroyl]-β-D-glucopyra-
noside
(2). Yellow powder; m.p.223-225°C; [α]D
23 -39.0° (c
0.05, MeOH). UV λmax (MeOH) nm (logε): 316 (2.25).
FAB-MS m/z: 595 [M +H]+ and 593 [M-H]−. 1H-NMR
and 13C-NMR spectra data see Table 3.
Table 2 AR, AGEs and COLO 320 inhibitory effects of
Compounds 1–9 and kaempferol-3-O-β-D-
glucopyranoside compared with Qu, AG and 5-Fu
Compounds IC50 (μM)
AR AGEs COLO 320
1 14.83 ± 0.28△ 57.06 ± 7.54 >100
2 2.39 ± 0.20*** 28.73 ± 2.96 24.10 ± 3.26
3 1.83 ± 0.02*** 8.48 ± 1.43* 22.56 ± 4.51△
4 1.22 ± 0.06*** 5.58 ± 0.48*** 3.53 ± 0.42**
5 0.43 ± 0.06*** 3.27 ± 0.09*** 2.86 ± 0.39**
6 0.63 ± 0.12*** 0.75 ± 0.21*** 2.43 ± 1.01**
kaempferol-3-O-glc 10.40 ± 0.18** 42.64 ± 3.73 58.84 ± 3.26
7 6.33 ± 1.10** 12.69 ± 5.17△△ 10.07 ± 1.84*
8 0.46 ± 0.01*** 4.43 ± 0.36*** 5.49 ± 0.23*
9 1.73 ± 0.14*** 5.21 ± 0.75*** 3.67 ± 0.09**
Qu 12.35 ± 1.06
AG 10.68 ± 1.06
5-Fu 8.79 ± 2.57
Data represent mean ± S.E.M. (n=3). IC50 of Compounds< IC50 of Positive Control
(Qu, AG, 5-Fu): ***p < 0.01 vs Positive Control, **p < 0.05 vs Positive Control,
*p >0.05 vs Positive Control; IC50 of Compounds> IC50 of Positive Control
(Qu, AG, 5-Fu): △△p > 0.05 vs Positive Control. △p > 0.01 vs Positive Control.
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(3). Yellow powder (40.0 mg). m.p.245-247°C. [α]D
22 -43.0°
(c 0.05, MeOH). UV λmax (MeOH) nm (logε): 318 (2.09).
FAB-MS m/z: 595 [M+H]+ and 593 [M-H]−. 1H-NMR
and 13C-NMR spectra data see Table 3.
kaempferol-3-O-[2''-O-(E)-p-coumaroyl]-β-D-glucopy-
ranoside
(4). Yellow powder. m.p.245-247°C. [α]D
20 -74.1° (c 0.13,
MeOH). UV λmax (MeOH) nm (logε): 316 (2.74). FAB-
MS m/z: 595 [M +H]+ and 593 [M-H]−. 1H-NMR and
13C-NMR spectra data see Table 3.
kaempferol-3-O-[2", 6"-di-O-(E)-p-coumaroyl]-β-D-glu-
copyranoside
(5). Yellow powder. m.p.196-199°C. [α]D
22 -119.6° (c 0.8,
MeOH). UV λmax (MeOH) nm (logε): 330 (2.38). FAB-
MS m/z: 741 [M +H]+. 1H-NMR and 13C-NMR spectra
data see Table 3.
kaempferol-3-O-[2", 6"-di-O-(E)-p-coumaroyl]-β-D-gala-
ctopyranoside
(6). Yellow powder. m.p.200-203°C. [α]D
22 -62.2° (c 0.1,
MeOH). UVλmax (MeOH) nm (logε): 323 (2.51); FAB-
MS m/z: 741 [M +H]+, 739 [M-H]− and 763 [M +Na]+;
ESI-Q-TOF MS m/z 741.1824 [M +H]+ (calcd 741.1819
for C39H33O15).
1H-NMR, 13C-NMR and 2D-NMR spec-
tra data see Table 1.
casuariin
(7). Off-white amorphous powder. m.p.245-248°C.
FAB-MS m/z: 783 [M-H]−. 1H-NMR ((CD3)2CO +D2O)
δ: 6.81 (1H, s), 6.62(1H, s), 6.47 (1H, s), 5.64 (1H, d, J =4.8 Hz), 4.72 (1H, m), 5.51 (1H, m), 5.13 (1H, dd, J = 8.4,
3.2 Hz), 4.18 (1H, m), 3.93 (1H, d, J = 12.0 Hz), 4.72 (1H,
d, J = 11.8 Hz). 13C-NMR ((CD3)2CO + D2O) δ: 115.9 (s),
115.6 (s), 115.6 (s), 114.5 (s), 126.8 (s), 126.5 (s), 124.6
(s), 119.4 (s), 116.6 (d), 108.2 (d), 106.6 (d), 104.8 (d),
145.5 (s), 145.2 (s), 144.7 (s), 144.6 (s), 143.9 (s), 143.8
(s), 143.2 (s), 143.0 (s), 138.3 (s), 136.2 (s), 135.2 (s),
134.4 (s), 169.8 (s), 169.3 (s), 168.3 (s), 165.3 (s), 66.6 (d),
76.6 (d), 70.3 (d), 76.5 (d), 67.8 (d), 67.9 (q).
casuarinin
(8). Off-white amorphous powder. m.p.244-246°C.
FAB-MS m/z: 935 [M-H]−. 1H-NMR ((CD3)2C O + D2O)
δ: 6.91 (1H, s), 6.64 (1H, s), 6.57 (1H, s), 7.16 (2H, s),
5.70 (1H, d, J = 4.8 Hz), 4.73 (1H, m), 5.47 (1H, m), 5.52
(1H, d, J = 8.8 Hz), 5.40 (1H, m), 4.20 (1H, d, J =
13.2 Hz), 4.89 (1H, m). 13C-NMR ((CD3)2CO + D2O) δ:
115.6 (s), 115.4 (s), 115.3 (s), 114.3 (s), 126.3 (s), 125.8
(s), 123.8 (s), 119.1 (s), 117.0 (s), 108.2 (d), 106.7 (d),
105.0 (d), 145.2 (s), 145.1 (s), 144.6 (s), 144.6 (s), 143.9
(s), 143.2 (s), 142.7 (s), 138.3 (s), 136.4 (s), 135.3 (s),
134.3 (s), 169.2 (s), 169.1 (s), 168.4 (s), 165.6 (s), 119.6
(s), 109.8 (d), 139.0 (s), 166.0 (s), 66.1 (d), 76.5 (d), 69.2
(d), 73.6 (d), 70.5 (d), 64.3 (q).
castalagin
(9). Off-white amorphous powder. m.p.243-245°C. FAB-
MS m/z: 935 [M+H]+ and 933 [M-H]−. 1H-NMR((CD3)
2CO+D2O) δ: 6.66 (1H, s), 6.65 (1H, s), 6.52 (1H, s), 5.57
(1H, d, J =4.4 Hz), 4.97 (1H, m), 4.92 (1H, m), 5.04 (1H, t,
J = 7.2 Hz), 5.44 (1H, d, J = 7.6 Hz), 3.94 (1H, d, J = 12.8),
4.80 (1H, m). 13C-NMR ((CD3)2CO +D2O) δ: 121.3 (s),
124.4 (s), 124.4 (s), 125.8 (s), 126.9 (s), 107.2 (d), 107.9
(d), 108.4 (d), 115.7 (s), 115.5 (s), 146.1 (s), 144.9 (s),
144.7 (s), 144.6 (s), 144.2 (s), 144.0 (s), 143.9 (s), 143.8 (s),
143.6 (s), 143.1 (s), 137.5 (s), 136.2 (s), 136.0 (s), 135.4 (s),
134.5 (s), 112.4 (s), 113.9 (s), 113.9 (s), 114.5 (s), 115.4 (s),
168.9 (s), 166.9 (s), 166.2 (s), 165.1 (s), 164.7 (s), 66.0 (d),
73.8 (d), 66.6 (d), 68.9 (d), 70.9 (d), 65.2 (q).
Discussion
Flavonoids 1–5 and compound kaempferol-3-O-β-D-
glucopyranoside were reported to have hypolipidemic,
anti-oxidant, anti-inflammatory, analgesic, and anti-
aging activities [18]. The relationship between their
structures and the efficiency was discussed. The pres-
ence of ortho-hydroxy group at B-ring, the double bond
at C2–C3 for C-ring, and the presence of C7-OH are
usually listed as important conditions for high AR in-
hibitory effects. Accordingly, the double bond of C2–C3,
ortho- or meta-hydroxy groups in B ring, or a glucose
unit are associated with the enhanced cytotoxicity [19].
According to the data for compounds 1–6, the presence
of p-coumaroyl groups would enhance the inhibitory ac-
tivity in three assays, therein, flavonoids with more p-
coumaroyl groups in structure are deemed to be the
Table 3 1H-NMR and 13C-NMR data of compounds 2-5
NO. 2 3 4 5
1H-NMR1 13C-NMR1 1H-NMR1 13C-NMR1 1H-NMR2 13C-NMR2 1H-NMR2 13C-NMR2
2 156.4 156.4 158.1 158.7
3 133.0 133.0 134.6 134.2
4 177.4 177.4 178.8 178.8
5 156.3 156.3 162.8 162.7
6 6.15 (1H, d, 1.9) 98.7 6.15 (1H, d, 1.9) 98.7 6.05 (1H, br.s) 100.4 6.05 (1H, br.s) 99.7
7 164.1 164.1 165.4 165.3
8 6.39 (1H, d, 1.9) 93.5 6.39 (1H, d, 1.9) 93.5 6.24 (1H, br.s) 94.5 6.25 (1H, br.s) 94.6
9 161.1 161.1 158.0 158.0
10 103.9 103.9 105.7 105.6
1′ 120.7 120.7 122.6 122.7
2′, 6′ 7.99 (2H, d, 9.2) 130.8 7.99 (2H, d, 9.2) 130.8 7.89 (2H, d, 8.8) 132.0 7.95 (2H, d, 8.8) 131.9
3′, 5′ 6.86 (2H, d, 9.2) 115.1 6.86 (2H, d, 9.2) 115.1 6.78 (2H, d, 8.8) 116.0 6.86 (2H, d, 8.8) 115.9
4′ 160.0 160.0 161.2 160.9
1′′ 5.45 (1H, d, 7.7) 100.9 5.45 (1H, d, 7.7) 100.9 5.57 (1H, d, 8.0) 99.6 5.65 (1H, d, 8.4 ) 100.3
2′′ 3.28 (1H, d, 7.7) 74.2 3.28 (1H, d, 7.7) 74.2 4.92 (1H, d, 8.0) 75.7 5.09 (1H, dd, 8.8,8.4) 75.6
3′′ 3.25 (1H, d, 7.7) 76.2 3.25 (1H, d, 7.7) 76.2 3.48 m 76.2 3.71 (1H, dd, 8.8,8.8) 76.1
4′′ 3.18 (1H, m) 69.9 3.18 (1H, m) 69.9 3.30 m (1H, d, 8.8) 71.5 3.44 (1H, dd, 8.8,8.8) 71.9
5′′ 3.38 (1H, m) 74.1 3.38 (1H, m) 74.1 3.21 m 78.6 3.59 (1H, m) 75.8
6′′ 4.28 (1H, dd, 12.0, 2.0) 63.0 4.28 (1H, dd, 12.0, 2.0) 63.0 3.67 m 62.5 4.23 (1H, br.d, 10.8) 64.1
4.03 (1H, dd, 12.0, 2.0) 4.03 (1H, dd, 12.0, 2.0) 3.46 m 4.37 (1H, br.d, 10.8)
1′′′ 124.9 124.9 127.1 126.9
2′′′, 6′′′ 7.37 (2H, d, 8.5) 130.1 7.37 (2H, d, 8.5) 130.1 7.34 (2H, d, 8.4) 131.0 7.30 (2H, d, 8.8) 131.0
3′′′, 5′′′ 6.79 (2H, d, 8.5) 115.6 6.79 (2H, d, 8.5) 115.6 6.70 (2H, d, 8.4) 116.6 6.80 (2H, d, 8.8) 116.6
4′′′ 159.8 159.8 160.9 160.8
7′′′ 7.34 (1H, d, 15.8) 144.6 7.34 (1H, d, 15.8) 144.6 7.55 (1H, d, 16.0) 146.6 7.40 (1H, d, 15.6) 146.3
8′′′ 6.11 (1H, d, 15.8) 113.6 6.11 (1H, d, 15.8) 113.6 6.25 (1H, d, 16.0) 115.0 6.07 (1H, d, 15.6) 114.5
9′′′ 166.1 166.1 168.1 168.5
1′′′′ 126.9
2′′′′, 6′′′′ 7.48 (2H, d, 8.8) 131.0
3′′′′, 5′′′′ 6.80 (2H, d, 8.8) 116.6
4′′′′ 160.9
7′′′′ 7.72 (1H, d, 16.0) 146.8
8′′′′ 6.44 (1H, d, 16.0) 115.1
9′′′′ 168.2
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agents.
Compounds 7, 8 and 9, as polyphenolic derivatives
showed remarkable inhibitory effects in three bioactive
systems, and the increasing number of galloyl groups in
the structure could increase their activity. Some studies
found that polyphenolic compounds possessed the potent
anti-oxidant and anti-cancer activities to a greater or lesser
extent [20], moreover, structure–activity relationships fortheir radical scavenging, anti-oxidant, anti-herbivore, and
anti-herpetic activities also had been discussed [21-23].
Here, they were found having a healthy value against can-
cer or diabetic complications.
Based on our results, the anti-diabetes complications
and anti-cancer activity of different parts of C. mollissina
could be attributed to its containing amount of flavo-
noids and polyphenolic derivatives especially with more
function groups in the structures. It is no doubt that as
Zhang et al. BMC Complementary and Alternative Medicine 2014, 14:422 Page 8 of 9
http://www.biomedcentral.com/1472-6882/14/422a food product the value for Ban li is not only for its nu-
trients but also for its functional values, including the
value of its shells and involucres, which would be poten-
tial sources of phenolic compounds for using either as
food additives or chemical medicines. We believe that
systematic and thorough investigations on functions of
Chinese chestnut are very necessary in future studies.
Conclusions
This paper aims to detail some standard procedures to
provide better scope for performing the anti-diabetes
complications and anti-cancer properties of C. mollissina.
The plant is thus a promising source of anti-diabetes com-
plications and anti-cancer drug besides indication that fla-
vonoids and polyphenolic acids are the compounds
responsible for these effects. Such findings are of extreme
importance in the strive for future development of potent,
safer and effective anti-diabetes complications and anti-
cancer agent.
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